Price
No data yet.
Social Signal Score
Analyst Ratings
21 analystsRevenue
$69.73M+522.32%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael D. Dale
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 622
- Beta
- 1.17
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 26.32
Financials
Revenue
$69.73M+522.3%Net Income
$-1.52MEBITDA
$-4.0KFree Cash Flow
$601.0KEPS (diluted)
$-0.03Shares Outstanding (diluted)
53.34M+76.9%Operating Expenses
$52.83MCash & Debt
$94.57MReturn of Capital
$0.00Dividend per Share
$1.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $225.21M | $-15.70M | $-0.34 |
| 2024 | $187.34M | $-9.96M | $-0.23 |
| 2023 | $159.01M | $-21.72M | $-0.51 |
| 2022 | $138.58M | $-28.95M | $-0.69 |
| 2021 | $127.36M | $-26.98M | $-0.65 |
| 2020 | $112.30M | $-23.79M | $-0.60 |
| 2019 | $106.71M | $-29.12M | $-0.74 |
| 2018 | $83.94M | $-22.40M | $-0.60 |
| 2017 | $60.43M | $-10.45M | $-0.31 |
| 2016 | $41.11M | $-14.41M | $-0.47 |
| 2015 | $27.33M | $-13.36M | $-0.51 |
| 2014 | $16.82M | $-17.71M | $-1.00 |
| 2013 | $10.95M | $-14.56M | $-1.08 |
| 2012 | $7.69M | $-9.42M | $-0.85 |
Valuation
AXGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-68.97%Social Signal Score
Mentions (7)
- Newszacks.com·5d ago·Neutral
AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026 ALACHUA, Fla. and TAMPA, Fla.
View source ↗ - Newszacks.com·21d ago·Positive
Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN) The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair ALACHUA, Fla. and TAMPA, Fla.
View source ↗ - Newsbenzinga.com·46d ago·Positive
Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair Axogen Inc. (NASDAQ:AXGN) on Thursday agreed to acquire a privately held medical device manufacturer, BioCircuit Technologies Inc., for $200 million in cash.
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
…of $208.7 Million Public Offering of Common Stock ALACHUA, Fla. and TAMPA, Fla., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced the pricing of an underwritten public offering of 4,910,000 shares of its common stock at a price to the public of $42.50 per share, before underwriting discounts and commissions. All of …
View source ↗ - Newsglobenewswire.com·46d ago·Positive
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies Acquisition adds NerveTape™, the 1st FDA-approved device for sutureless peripheral nerve repair, broadening Axogen's addressable market within its focus markets
View source ↗
Earnings
Wed, Oct 28(tomorrow)
Consensus estimate $0.13 per share
Typical surprise -1.2% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$0.12 vs $0.12miss
- Tue, Apr 28$0.07 vs $0.12miss
- Tue, Feb 24$0.07 vs $0.09miss
- Wed, Oct 29$0.12 vs $0.09beat
- Tue, Aug 5$0.12 vs $0.06beat
- Thu, May 8$-0.02 vs $-0.01miss
Estimates and results for AXGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AXGN officers and directors.
- Bought
- —
- Sold
- $9.0m
0 trades
17 trades
- Tyndall Joseph A.sold
- Wendell Amy Mcbridesold
- Began Marc Asold
- Weiler Kathy Johnsonsold
- Wendell Amy Mcbridesold
- Johnson Johnsold
- Weiler Kathy Johnsonsold
- Kemp Jenssold
83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (377d later)Buy$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (308d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.